Galmed Pharmaceuticals (GLMD) Equity Average (2016 - 2020)

Galmed Pharmaceuticals' Equity Average history runs 5 years deep, the most recent figure standing at $48.9 million for Q4 2020.

• In Q4 2020, Equity Average fell 33.59% year-over-year to $48.9 million; the TTM figure through Dec 2020 stood at $48.9 million (down 33.59% YoY), while the FY2025 annual figure was $16.1 million, up 6.3% from the prior year.
• Equity Average was $48.9 million for Q4 2020 at Galmed Pharmaceuticals, down from $56.8 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $90.9 million in Q3 2018 to a low of $6.4 million in Q3 2017.
• Historically, Equity Average has averaged $46.5 million across 5 years, with a median of $52.3 million in 2018.
• The sharpest annual moves came in 2017 and 2018: Equity Average plunged 57.36% in 2017, then surged 1323.13% in 2018.
• A 5-year view of Equity Average shows it stood at $13.3 million in 2016, then declined by 16.08% to $11.2 million in 2017, then soared by 700.12% to $89.3 million in 2018, then declined by 17.56% to $73.6 million in 2019, then slumped by 33.59% to $48.9 million in 2020.
• The last three Equity Average figures came in at $48.9 million (Q4 2020), $56.8 million (Q3 2020), and $62.0 million (Q2 2020), per Business Quant data.